Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.48 |
| ▸ | PTGFR | P43088 | 2/20 | 0.48 |
| ▸ | PTGIR | P43119 | 2/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124437 | 1.00 | PTGS2 (0.55) | PTGS2CA1CA2NFKB1CA4 | |
| SCHEMBL5009953 | 0.87 | PTGS2 (0.48) | PTGS2CA1CA2NFKB1CA4 | |
| SCHEMBL7004841 | 0.85 | PTGS2 (0.55) | PTGS2NFKB1MAPTLMNANPC1 | |
| SCHEMBL7004850 | 0.85 | PTGS2 (0.55) | PTGS2NFKB1MAPTLMNANPC1 | |
| SCHEMBL211297 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL29393232 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL12852987 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL322878 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL9652685 | 0.83 | PTGS2 (0.54) | PTGS2NFKB1MAPTLMNANPC1 | |
| SCHEMBL11462614 | 0.82 | HDAC1 (0.62) | CA1CA2NFKB1CA4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426243-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156165-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9598412-B2 | Spiroindoline compounds for use as anthelminthics | INTERVET INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2531506-B1 | Spiroindoline compounds for use as anthelminthics | INTERVET INT BV (NL) | 2014-05-14 | — | — | EP | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2265588-B1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| CN-101724007-A | Oleanolic acid derivatives and application thereof serving as alpha-glucosidase inhibitor | UNIV CHINA PHARMA | 2010-06-09 | — | — | CN | disclosed |
| WO-2009141782-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009108332-A1 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2005019177-A1 | AMINOPIPERIDINE AMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| JP-2004534057-A | Low-poisonous showing oral dosage form of gaba analogue prodrug | — | 2004-11-11 | — | — | JP | disclosed |
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-5863936-A | HETEROCYCLIC ENZYME INHIBITORS AS ANTICANCER AGENTS | GERON CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| US-5677306-A | ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS | RHONE-POULENC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | PTGS2 156/4885CA1 3866/4885CA2 2006/4885 |
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | PTGS2 891/4885CA1 1085/4885CA2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.